Last reviewed · How we verify
ILV-095
At a glance
| Generic name | ILV-095 |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects (PHASE1)
- Study Evaluating Single Doses of ILV-095 in Healthy Japanese Male Subjects (PHASE1)
- Study Evaluating Single Doses of ILV-095 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ILV-095 CI brief — competitive landscape report
- ILV-095 updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI